TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
One Percent Rule Checklist For Safer Forex Trading Risk 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
South Korean biotech company Celltrion Inc. plans to merge with its two affiliates, Celltrion Healthcare Co. and Celltrion Pharma Inc., to establish a holding company structure by the end of 2021.
Celltrion Group Chairman Seo Jung-jin would establish Celltrion Healthcare Holdings by investing his stakes in Celltrion Healthcare, making the holding company its largest shareholder.
Celltrion Group Chairman Seo Jung-Jin would hold 11.21 percent in Celltrion Healthcare Holdings, which in turn would have a 24.33 percent stake.
The process would be hastened when requirements for relevant laws regarding anti-monopoly and fair trade are met.
Seo noted that the merger would depend upon the wishes of shareholders.
Celltrion is conducting phase one clinical trials on patients of its coronavirus treatment, CT-P59, to evaluate the safety and efficacy of the treatment.
